Investing in life changing medicines

Humanity will always depend on medicines. Continuous innovation in the biotech sector is a given, bringing better medicines to the market all the time. Aescap is able to select those companies that are developing tomorrow’s groundbreaking medicines. Thereby it can achieve excellent returns, without taking large risks. Aescap is heavily involved with the companies it invests in, acting as a private equity investor on the stock market, and as an activist where needed.

The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. The funds are supervised by an AIFM and managed by an experienced investment team with an excellent track record. The members of the investment team significantly invest in the Aescap funds themselves. The name Aescap is derived from ‘Aesculapius’, the Roman god of Medicine, and ‘Capital’.

Sustainable investing

The Aescap funds are classified as article 8 fund, according to the Sustainable Finance Disclosure Regulation (SFDR). In addition to their financial aim to gain value, they promote a social characteristic by investing in companies that develop treatments for diseases with a high unmet medical need.

Investments can have a very positive impact on the quality of life of millions of people.

Update via webcast

We regularly organise information meetings for existing and potential investors. In these meetings we share our investment philosophy as well as methodology. The next meeting takes place on October, 17th.

Meet the investment team

The Aescap investment team, led by portfolio manager Patrick Krol, consists of experienced professionals with different backgrounds in the health care industry. We aim to provide a good financial return to our investors, and in parallel contribute to improving the well-being of millions of people. Our team members invest in the Aescap funds themselves with over 25 million euro.

Interested in investing in Aescap funds?

Subscribe to our newsletter here.



    Latest news

    Aescap funds >10% up in 1 day

    On October 16th, the Aescap Life Sciences fund gained 11,7% and the Genetics fund 12,5%. This rise was driven by our holdings in ProQR Therapeutics (in both funds) and Wave Life Sciences (Genetics fund). The increase in both companies was caused by data from a clinical trial for a Wave Life Sciences medicine. This product

    Home